During the pandemic, the growth of most biopharma businesses had slowed down, except for COVID-19 vaccines and therapies. Yet, exosome-related deals have thrived even under such difficult circumstances, shedding light on the tremendous potential of startups and ground-breaking technologies.  Who are the buyers? And who are the rising stars?

Exosome as IVD: M&A
The most significant med-tech application of exosomes is the ExoDx Prostate Test (EPI), developed by Exosome Diagnostics Inc. (Exosome Dx), now part of Bio-Techne Corp. (NASDAQ: TECH).
EPI, the first exosome-based liquid biopsy test to receive FDA breakthrough